Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GBL

This article was originally published in The Tan Sheet

Executive Summary

House Commerce/Oversight & Investigations Subcommittee scheduled to hold hearing March 11 on "date rape" drugs, including GHB and its precursor GBL. The subcommittee "will study whether the federal government is taking enough action to combat the use of date rape drugs." In a Jan. 21 "Talk Paper," FDA requested that seven manufacturers of GBL marketed as dietary supplements, including RenewTrient, voluntarily recall their products after numerous adverse reactions were reported ("The Tan Sheet" Jan. 25, p. 6). After the agency sent out four warning letters, all but one of the firms complied ("The Tan Sheet" Feb. 1, p. 3). The hearing is scheduled for 9:30 a.m
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS089495

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel